Aims: Dydrogesterone is a retro-progesterone preparation widely used for over a half century. We sought to evaluate the efficacy and safety of dydrogesterone in Japanese women with dysmenorrhea. Methods: This study was conducted as an open-label, single-arm, multicenter study. One dydrogesterone 5-mg tablet (Duphaston) was administered orally twice daily for 21 days from the 5th to 25th day of each menstrual cycle. A total of 44 (safety analysis) and 31 patients (efficacy analysis) were enrolled. Total dysmenorrhea score, dysmenorrhea subscale scores, dysmenorrhea visual analog scale, severity of menstruation-related lower abdominal pain, low back pain, headache, and nausea/vomiting, basal body temperature, and serum estradiol and progesterone levels were evaluated. Results: Baseline of the total dysmenorrhea score was 4.61, which went down over time following the administration of dydrogesterone, and the decrease was statistically significant at and after 2nd cycle of menstruation. Mean change from baseline at the final evaluation point was −1.84 (P < 0.001). Severity of menstruation-related lower abdominal pain, low back pain, headache, and nausea/vomiting, in the evaluated menstruation cycles tended to decrease over time. Basal body temperature showed a biphasic pattern in 70% at baseline, 50% in 2nd menstruation cycle, and 61% in 5th menstruation cycle, and at least half of the patients may have had ovulation during the treatment. Incidence of adverse drug reactions was 31.8%, and the most common adverse event was metrorrhagia. Conclusion: Dydrogesterone is efficacious, safe, and clinically beneficial in patients with dysmenorrhea, thereby indicating that dydrogesterone can be considered as a treatment option for patients with dysmenorrhea.
Introduction
Dysmenorrhea is defined as a pathological symptom associated with menstruation, marked by abdominal cramping and pain during the menstrual period that interfere with the activities of daily living. Associated general symptoms, such as nausea, vomiting, lumbago, diarrhea, and headache, are also common. 1 Menstrual pain is known to affect the majority of young women. Generally, menstrual pain tends to be initially absent, but many women start having intense pain 2 to 3 years after menarche when menstrual cycles, each cycle's duration, and amount stabilize and ovulation cycles are established.
Dysmenorrhea can be divided into two types: primary dysmenorrhea (occurring in the absence of organic abnormalities) and secondary dysmenorrhea (resulting from organic diseases, such as uterine fibroid, endometriosis, adenomyosis, and intrapelvic inflammation due to chlamydia infection, genital malformation, etc.). 1 In adolescents, dysmenorrhea is mostly functional, and suggested causes include excessive prostaglandin (PG) production by the endometrium during menstruation. The etiology of primary dysmenorrhea includes an excess or imbalance in the amount of PG secretion from the endometrium during menstruation. PG and their metabolites in general circulation can cause headache and gastro-intestinal symptoms as well as locally excessive uterine contractions that can be painful.
One study, conducted with the support of the Japan Ministry of Health and Welfare, revealed that menstrual pain requiring pain medication occurs in 33% of menstruating Japanese women. In 6% of women, pain medications were ineffective and bed rest was needed. The study results suggest that onethird of women who menstruate may require medical intervention. 2 Ikeda et al., reporting the results of a questionnaire survey of menstrual pain among high-school students, revealed that 90.8% of students experienced menstrual pain and that pain affected the daily activities of 51.8%. The incidence of menstrual pain increased in the 3rd-grade students (17 to 18 years old) compared with the 1st-and 2nd-grade students. 3 Usually, menstrual pain can be effectively reduced by the use of nonsteroidal anti-inflammatory drugs. Because 20% to 30% of dysmenorrhea cases do not respond to nonsteroidal anti-inflammatory drugs, Chinese herbal medicine and other therapies may be used. For individuals with persistent pain that interferes with the activities of daily living, hormonal drugs such as oral contraceptive (OC) or low-dose estrogen/progestin (LEP) preparations (e.g., Lunabell Tablets LD, Lunabell Tablets ULD, Yaz Tablets, and Yaz Flex; LEP are prescribed and covered by health insurance in Japan) may be prescribed to inhibit ovulation and cause reduced or no menstrual bleeding. If necessary, laparoscopic diagnosis of endometriosis and surgery may be performed.
By preventing ovulation, LEP or OC suppresses the progesterone-driven proliferation of the secretory endometrium, resulting in a decrease in the visual analog scale (VAS) score. 4, 5 Recently, while low-dose hormone preparations are becoming increasingly popular, treatment with low-dose hormone preparations has been suggested to be associated with a risk of venous thrombosis, and other adverse reactions. Under these circumstances, dydrogesterone (Duphaston), a hormone preparation available since 1965 for the treatment of not only dysmenorrhea but also endometriosis, has been attracting attention. 6 In particular, dydrogesterone does not inhibit ovulation, and does not affect basal body temperature (BBT). Thus, even while on treatment, ovulation may occur and pregnancy is possible. Although dydrogesterone is an old retro-progesterone preparation used for over a half century in Japan as well as in Europe, almost no clinical evidence in Japanese patients has been collected. Currently, new clinical data are requested mainly by gynecologists, for reverification of the efficacy, safety, and fertility improving the effect of dydrogesterone. For this reason, the clinical study was planned to re-evaluate the efficacy and safety of dydrogesterone in patients with dysmenorrhea.
Materials and Methods
The institutional review board of Tottori University Faculty of Medicine approved this project (No. 16058005). This study was conducted as an openlabel, single-arm, multicenter study. Informed consent was obtained two cycles before the 1st treatment cycle, and screening examination was performed one cycle before the 1st menstrual cycle. Out of 47 patients for safety analysis and 44 patients for efficacy analysis, 44 and 31 patients were enrolled from July 2016 to December 2017 after they were confirmed to fulfill the inclusion criteria and not to meet any of the exclusion criteria. The duration of the study treatment period was four menstrual cycles. One dydrogesterone 5-mg tablet was administered orally twice daily (after breakfast and evening meals) for 21 days from the 5th to 25th day of each menstrual cycle. This treatment was repeated for four consecutive menstrual cycles.
Inclusion criteria are as follows: (i) women aged between 20 and 45 years; (ii) patients with a diagnosis of primary dysmenorrhea or secondary dysmenorrhea; (iii) patients with a menstrual cycle of 28 AE 3 days; (iv) patients with a total dysmenorrhea score of greater than 3 at the time of enrollment; (v) patients who provided written consent and are capable of following the study requirements during participation in the study, undergoing protocol-specified physical examination and other tests, and reporting any symptoms or other changes.
Exclusion criteria are as follows: (i) patients with a history of serious liver disorder or disease; (ii) patients with a history of confirmed or suspected hypersensitivity to any ingredients of the study drug or Loxonin (loxoprofen sodium hydrate) Tablets 60 mg, or patients who are contraindicated for these drugs; (iii) patients with a history of cardiac or renal disease; (iv) patients with porphyria; (v) patients with a history of peptic ulcer; (vi) patients with any severe laboratory test abnormality; (vii) patients with bronchial asthma or aspirin asthma; (viii) patients with ulcerative colitis or Crohn disease; (ix) patients with pregnancy or suspected pregnancy at the time of enrollment; (x) breastfeeding women; (xi) patients who participated in another clinical study within 3 months (84 days) before enrollment in this study; (xii) patients who used any of the following drugs within 2 months (56 days) before enrollment; (xiii) hormone preparations primarily containing progesterone or estrogen, low-dose pills, moderate-dose pills, GnRH agonists, testosterone derivatives, estrogen antagonists and aromatase inhibitors, Chinese herbal medicine indicated for dysmenorrhea; (xiv) patients who underwent transvaginal alcohol sclerosis or laparotomy or laparoscopic surgical treatment for endometriosis within 2 months (56 days) before enrollment. The protocol-specified final tests and observations after the end of the study treatment were performed at the end of the 5th menstrual cycle.
Of 47 patients who provided informed consent, 44 patients were judged eligible and enrolled in the study. While 10 patients discontinued the study after the treatment with dydrogesterone was started, 34 patients completed the treatment. The reasons for the discontinuation of dydrogesterone treatment were no return to site (six patients), withdrawal of consent (two patients), adverse event onset (one patient) and discontinued by an investigator (one patient). The safety analysis set consisted of 44 patients who received dydrogesterone, and the full analysis set consisted of 31 patients, after exclusion of 12 patients who had no efficacy data after administration and one patient who used oral dydrogesterone before the start of the study. Therefore, the safety analysis set consisted of 44 patients. The full analysis set consisted of all patients who were enrolled in this study and were started on the study drug, with the exclusion of the patients not fulfilling the inclusion criteria, meeting any of the exclusion criteria, having no available data before the start of study drug administration, or having no data after the start of study drug administration.
For the primary endpoint, i.e., the change from baseline in the total dysmenorrhea score 5,7 was analyzed using a paired t-test (Table 1) . For the secondary endpoints, as the efficacy evaluation, total dysmenorrhea score, the dysmenorrhea intensity score, and analgesic usage score, frequency distributions of the dysmenorrhea subscale score and dysmenorrhea VAS score were analyzed using a paired t-test at each time point of evaluation. In addition, the severity of menstruation-related lower abdominal pain, low back pain, headache, and nausea/vomiting as the worst severity of each symptom in the evaluated menstruation cycle were analyzed using Fisher exact test (Table 2 ). Dysmenorrhea and severity of menstruation-related symptoms during menstruation were recorded every day, and analyzed using the data at the time of worst severity in the evaluated menstrual cycle. Changes in BBT, serum estradiol (E2) and progesterone (P4) levels were analyzed in each patient over time. Serum E2 and P4 concentrations were measured in the menstrual period of cycles, −1, 2 and 4 in the study drug administration period. Because it has been known that dydrogesterone can induce the ovulation and does not raise BBT in anovulatory women, E2 and P4 concentrations were assessed. For the secondary endpoints, as safety evaluation and adverse events were coded to the preferred terms of MedDRA/J (Ver. 20.1), and summarized by preferred term. The frequency and incidence of adverse events and adverse drug reactions were calculated by event term and seriousness. Laboratory test values and vital signs were analyzed using one sample Wilcoxon test and one sample t-test. Data were shown as mean AE SD. P < 0.05 was set as statistically significant.
Results
The efficacy of dydrogesterone in patients with dysmenorrhea was evaluated in a total of 31 patients, after exclusion of 12 patients for no available efficacy data after administration and one patient for use of oral dydrogesterone before the start of the study, from 44 patients given dydrogesterone. The baseline characteristics of the study subjects included a mean age of 31.6 AE 6.1 years, a mean menstrual cycle duration of 28.4 AE 4.7 days, a mean menstrual bleeding duration of 5.9 AE 4.7 days, a mean total dysmenorrhea score of 4.6 AE 1.3, and a mean dysmenorrhea VAS score of 54.7 AE 23.2 mm. Administration of dydrogesterone during four menstrual cycles in women with primary or secondary dysmenorrhea led to improvement in total dysmenorrhea score and dysmenorrhea VAS immediately after the start of administration.
In terms of the primary endpoint, i.e., the change from baseline in the total dysmenorrhea score at final evaluation, at baseline (i.e., one menstrual cycle before the 1st), the total dysmenorrhea score was 4.61 AE 1.28. The mean change (95% confidence interval) was −1.84 (−2.54, −1.13), showing a statistically significant decrease (P < 0.001) (Fig. 1a) . As for secondary endpoints, the change from baseline in the total dysmenorrhea score over time also showed decrease over time after administration of dydrogesterone, and the decrease was significant at and after the 2nd cycle of menstruation. The decrease was greatest at the 4th menstruation cycle, i.e., at the end of the study treatment [−2.18 (95% confidence interval, −2.77, −1.60)]. The observed significant decrease was maintained up to the 5th menstruation cycle, i.e., the post-treatment observation period, indicating the efficacy of dydrogesterone (Fig. 1a) .
The dysmenorrhea intensity score, which was one of the dysmenorrhea subscale scores, decreased over time up to the 2nd menstruation cycle and thereafter remained essentially unchanged. At and after the 1st menstruation cycle, the dysmenorrhea intensity score was significantly lower than baseline (Fig. 1b) . In addition, the analgesic usage score, which was also one of the dysmenorrhea subscale scores, decreased over time after administration of dydrogesterone, and was significantly lower than baseline at and after the 2nd menstruation cycle (Fig. 1c) . These data verified that dydrogesterone can improve both the intensity of dysmenorrhea and the usage of analgesics.
The dysmenorrhea VAS score decreased over time after administration of dydrogesterone, and the decrease was significant at and after the 2nd cycle of menstruation. The decrease was greatest at the 4th menstruation cycle, i.e., at the end of the study Fig. 1d ). Similar to the improvement in the total dysmenorrhea score, the dysmenorrhea VAS score showed significant decrease. The efficacy of dydrogesterone on dysmenorrhea was proved by the different measures. For all of menstruation-related lower abdominal pain, low back pain, headache and nausea/vomiting, the severity in the evaluated menstruation cycles tended to decrease over time, although none showed a significant decrease from baseline (Fig. 1e) . The BBT showed a biphasic pattern in 70% (25/33 patients) at baseline, 50% (15/30 patients) in the 2nd menstruation cycle, and 61% (19/31 patients) in the 5th Figure 1 Legend on next page. menstruation cycle, and at least half of the patients may have had ovulation during the treatment. In Figure 2a and b, the changes in the serum E2 or P4 concentrations over time are shown for all patients at cycle −1; a subset of the patients with a nonbiphasic pattern of BBT in both the 2nd and 4th menstruation cycles; and a subset of the patients with a biphasic pattern of BBT in either or both of the 2nd and 4th menstruation cycles. Both E2 and P4 levels in blood tended to be higher in patients who showed a biphasic pattern of BBT. Furthermore, the number of patients who became pregnant was evaluated as the exploratory endpoint, although there were no reports of pregnancy during the study treatment period. On the basis of the above data, dydrogesterone does not suppress ovulation during administration, unlike OC/LEP or GnRH agonists (Fig. 2a,b) .
The safety of dydrogesterone was evaluated in all of the 44 patients given dydrogesterone in this study. The incidence of adverse events was 40.9% (18/44 patients), and the incidence of adverse drug reactions was 31.8% (14/44 patients). The most common adverse event was metrorrhagia (29.5%; 13/44 patients), followed by viral upper respiratory tract infection (6.8%; 3/44 patients). All adverse events were confirmed to have disappeared, resolved or improved. When the adverse events were classified by severity, the highest severity in individual patients was severe in 6.8% (3/44 patients), moderate in 6.8% (3/44 patients) and mild in 27.3% (12/44 patients). Severe adverse events were lower abdominal pain, pharyngitis bacterial and postural orthostatic tachycardia syndrome. Similarly, when adverse drug reactions were classified by severity, the highest severity in individual patients was moderate in 4.5% (2/44 patients) and mild in 27.3% (12/44 patients), while no adverse drug reactions were assessed as severe.
During the administration of dydrogesterone, none of the changes in laboratory test values or vital signs were assessed as abnormal. Significant changes from baseline were observed at the 5th menstruation cycle for white blood cell count, AST, fibrinogen, plasminogen activity, APTT, AT-III activity, and body weight. However, none of these changes were regarded as clinically meaningful, because the abnormal changes were small for all these parameters.
Discussion
In the present study, we confirmed the evidence that dydrogesterone effectively reduced dysmenorrhea pain symptoms and did not suppress ovulation during the oral administration. We demonstrated for the 1st time the evidence that dydrogesterone is the only hormonal drug which can be allowed to get pregnant during its administration, and have the efficacy and safety for the treatment of endometriosis with dysmenorrhea.
Cyclic application of dydrogesterone has also been shown to induce regular menstruation with symptomatic relief, reduced blood loss, and reduce days of Figure 1 Assessment of dysmenorrhea and severity of menstruation-related symptoms. (a) Change from baseline in the total dysmenorrhea score. At baseline (i.e., one menstrual cycle before the 1st), the total dysmenorrhea score was 4.61 AE 1.28. The mean (95% confidence interval) change from baseline at final evaluation was −1.84 (−2.54, −1.13), showing a statistically significant decrease (P < 0.001). The mean (95% confidence interval) change from baseline at the 2nd, 3rd, 4th, and 5th cycles of menstruation was shown. The total dysmenorrhea score decreased over time after administration of dydrogesterone, and the decrease was statistically significant at and after the 2nd cycle of menstruation (P < 0.001). (b) Change from baseline in the dysmenorrhea intensity score. The dysmenorrhea intensity score at baseline was 2.32 AE 0.54. The mean (95% confidence interval) change from baseline at the 2nd, 3rd, 4th, and 5th cycles of menstruation was .26), respectively. After administration of dydrogesterone, the dysmenorrhea VAS score decreased over time, and the decrease was statistically significant at and after the 2nd cycle of menstruation (P = 0.004 for the 2nd menstruation cycle, P < 0.001 for the 3rd and later menstruation cycles). (e) Changes in the severity of menstruation-related lower abdominal pain, low back pain, headache, and nausea/vomiting. The severity of these symptoms in the evaluated menstruation cycles tended to decrease over time, although none showed a significant decrease from baseline by Fisher exact test.
bleeding in women with dysmenorrhea. 8 Biologically, dydrogesterone treatment represses reactive oxygen species formation 9 and exerts modulating effects on nitric oxide synthesis and on the expression of endothelial nitric oxide synthase. 10 This can be one of the mechanisms of the various beneficial effects of dydrogesterone. Moreover, the results of a systematic review and a randomized controlled trial indicated that the oral dydrogesterone therapy can effectively prevent threatened miscarriage in pregnant women. 11, 12 The dysmenorrhea score (level of dysmenorrhea and use of analgesics) and the score for the severity for menstruation-related symptom (level of lower abdominal pain, low back pain, headache, and nausea/vomiting) were different methods to assess the pain and discomfort. The total dysmenorrhea score decreased over time after administration of dydrogesterone, and the decrease was statistically significant at and after the 2nd cycle of menstruation (Table 1 and Fig. 1a) . On the other hand, the severity of these symptoms in the evaluated menstruation cycles tended to decrease over time, although none showed a significant decrease from baseline (Table 2 and Fig. 1e ). As the limitation of this clinical study, there are several issues regarding the small sample size, the lacking control subjects, the subjects included primary and secondary dysmenorrhea, and the possibility of including anovulatory women.
The same pain score system has been used in the clinical trial of the LEP formula containing norethisterone/ethinylestradiol (Lunabell Tablets LD: Lunabell LD). The change in the total dysmenorrhea score from baseline at the last administration of the 5th menstruation cycle in the Lunabell study was −2.6, which was almost comparable to dydrogesterone. The change in the VAS score was −36.0 mm in the Lunabell study, indicating a slightly weaker effect of dydrogesterone. 7 As the limitation of this study, considering the small sample size of 31 patients included in the efficacy analysis, further investigation with a larger sample size is necessary to compare the effects.
The incidence of adverse drug reactions observed in a clinical trial of Lunabell LD in patients with dysmenorrhea associated with endometriosis was 87.9% (174/198 patients), and major adverse drug reactions were irregular genital bleeding (59.1%; 117 patients), nausea (26.3%; 52 patients), headache (16.2%; 32 patients), oligomenorrhea (14.6%; 29 patients), abdominal pain upper (8.6%; 17 patients), breast discomfort (8.1%; 16 patients), and menorrhagia (7.1%; 14 patients) (at approval in April 2008). 4 Thus, dydrogesterone was indicated to be well tolerated. For the treatment of endometriosis, the dose of dydrogesterone was set 10 mg/day for 21 days (from day 5 to 25 of menstruation cycle) in the previous studies. The cases of pregnancy during or after dydrogesterone treatment were reported. 13 Therefore, in this study, we set this dosage and duration not to avoid the possibility of pregnancy during treatment. There were no deaths or severe side effects in this study. Serious adverse events reported in this study were bacterial pharyngitis in one patient and postural orthostatic tachycardia syndrome in one patient. These events were serious because of hospitalization for treatment or prolongation of existing hospitalization, and both events were assessed as causally unrelated to the study drug. Both events were confirmed to have resolved or improved. The only adverse event leading to discontinuation was the serious adverse event of postural orthostatic tachycardia syndrome in one patient. As the adverse events of other progestins which are considered to be effective for dysmenorrhea, the occurrences of severe uterine bleeding by dienogest and breast cancer or thrombosis by medroxyprogesterone acetate have been reported. However, in the present study, such adverse events were not appeared.
Treatment of dydrogesterone during four menstrual cycles in women with primary or secondary dysmennorhea led to improvement with the efficacy maintained up to the 5th menstruation cycle. Progestogens have been considered as the alternatives, because they are inexpensive and may have a better side effect profile than other choices. While no published data exist regarding dydrogesterone for dysmenorrhea in Japanese women, this study proved that dydrogesterone is efficacious, safe, and clinically beneficial in patients with dysmenorrhea, thereby indicating that dydrogesterone can become a treatment option for the patients with dysmenorrhea.
